Page 7 - Nasdaq Crsp News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq crsp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Crsp Today - Breaking & Trending Today

Brokers Issue Forecasts for CRISPR Therapeutics AG's FY2024 Earnings (NASDAQ:CRSP)

CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) – Equities research analysts at Leerink Partnrs lowered their FY2024 earnings per share (EPS) estimates for shares of CRISPR Therapeutics in a research note issued to investors on Wednesday, January 17th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings of ($7.54) per share […] ....

Leerink Partnrs , Samarth Kulkarni , Therapeutics Company Profile , Tradewinds Capital Management , Geneos Wealth Management Inc , Headlands Technologies , Royal Bank , Cantor Fitzgerald , Blue Trust Inc , Free Report , Get Free Report , Wealth Management , Capital Management , Crispr Therapeutics , Nasdaq Crsp , Earnings Estimates ,

Sumitomo Mitsui Trust Holdings Inc. Sells 67,887 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Sumitomo Mitsui Trust Holdings Inc. reduced its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 1.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,465,470 shares of the company’s stock after selling 67,887 shares during the period. Sumitomo […] ....

Morgan Stanley , Royal Bank , Pinnacle Holdings , Geneos Wealth Management Inc , Sumitomo Mitsui Trust Holdings Inc , Needham Company , Cantor Fitzgerald , Bluepath Capital Management , Exchange Commission , Sumitomo Mitsui Trust Holdings , Free Report , Mitsui Trust Holdings , Wealth Management , Path Capital Management , Get Free Report , Visit Holdingschannel , Crispr Therapeutics , Nasdaq Crsp , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,

CRISPR Therapeutics AG (NASDAQ:CRSP) Receives $68.39 Consensus PT from Brokerages

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has received a consensus rating of “Hold” from the eighteen research firms that are covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, six have issued a hold rating and ten have issued a buy rating on the company. The […] ....

Tradewinds Capital Management , Morgan Stanley , Headlands Technologies , Geneos Wealth Management Inc , Cantor Fitzgerald , Bluepath Capital Management , Get Free Report , Marketbeat Ratings , Wealth Management , Capital Management , Get Free , Crispr Therapeutics , Nasdaq Crsp ,

ARK Investment Management LLC Sells 175,329 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

ARK Investment Management LLC cut its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 2.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,163,118 shares of the company’s stock after selling 175,329 shares during the quarter. CRISPR […] ....

Pinnacle Holdings , Eversource Wealth Advisors , Royal Bank , Securities Exchange Commission , Geneos Wealth Management Inc , Ark Investment Management , Needham Company , Investment Management , Therapeutics Company Profile , Free Report , Wealth Management , Source Wealth Advisors , Get Free Report , Crispr Therapeutics , Nasdaq Crsp , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,

CRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus Recommendation of "Hold" by Brokerages

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has received a consensus recommendation of “Hold” from the eighteen brokerages that are covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, six have given a hold rating and ten have given a buy rating to the company. The average […] ....

Geneos Wealth Management Inc , Tradewinds Capital Management , Headlands Technologies , Cantor Fitzgerald , Morgan Stanley , Bluepath Capital Management , Therapeutics Company Profile , Get Free Report , Marketbeat Ratings , Wealth Management , Capital Management , Get Free , Crispr Therapeutics , Nasdaq Crsp ,